Abstract:Background The triple negative breast cancer (TNBC) is the most malignant subtype of breast cancer with high aggressiveness. Although paclitaxel-based chemotherapy scenario present the mainstay in TNBC treatment, paclitaxel resistance is still a striking obstacle for cancer cure. So it is imperative to probe new therapeutic targets through illustrating the mechanisms underlying paclitaxel chemoresistance. Methods The Single cell RNA sequencing (scRNA-seq) data of TNBC cells treated with paclitaxel at different points were downloaded from the Gene Expression Omnibus (GEO) database. The Seurat R package was used to filter and integrate the scRNA-seq expression matrix. Cells were further clustered by the FindClusters function, and the gene marker of each subset was defined by FindAllMarkers function. Then, the hallmark score of each cell was calculated by AUCell R package, the biological function of the highly expressed interest genes was analyzed by the DAVID database. Subsequently, we performed pseudotime analysis to explore the change patterns of drug resistance genes and SCENIC analysis to identify the key transcription factors (TFs). Finally, the inhibitors of which were also analyzed by the CTD database. Results We finally obtained 6 cell subsets from 2798 cells, which were marked as AKR1C3+, WNT7A+, FAM72B+, RERG+, IDO1+ and HEY1+HCC1143 cell subsets, among which the AKR1C3+, IDO1+ and HEY1+ cell subsets proportions increased with increasing treatment time, and then were regarded as paclitaxel resistance subsets. Hallmark score and pseudotime analysis showed that these paclitaxel resistance subsets were associated with the inflammatory response, virus and interferon response activation. In addition, the gene regulatory networks (GRNs) indicated that 3 key TFs (STAT1, CEBPB and IRF7) played vital role in promoting resistance development, and five common inhibitors targeted these TFs as potential combination therapies of paclitaxel were identified. Conclusion In this study, we identified 3 paclitaxel resistance relevant IFs and their inhibitors, which offers essential molecular basis for paclitaxel resistance and beneficial guidance for the combination of paclitaxel in clinical TNBC therapy.

Drug resistance‐related gene targets and molecular mechanisms in the A2780/Taxol‐resistant epithelial ovarian cancer cell line

Exploring Specific miRNA-mRNA Axes With Relationship to Taxanes-Resistance in Breast Cancer

Establishment of a new paclitaxel resistant cell line of human ovarian carcinoma and preliminary observation of its biology.

Notch1 Affects Chemo-resistance Through Regulating Epithelial-Mesenchymal Transition (EMT) in Epithelial Ovarian Cancer Cells

TXNDC17 Promotes Paclitaxel Resistance Via Inducing Autophagy in Ovarian Cancer

Paclitaxel Resistance in Ovarian Cancers Relies on a PGAM1 Mediated Glycolytic Metabolism

Overexpression of Glycogen Synthase Kinase-3 in Ovarian Carcinoma Cells with Acquired Paclitaxel Resistance

Down-regulation of UTP23 Promotes Paclitaxel Resistance and Predicts Poorer Prognosis in Ovarian Cancer.

Mechanistic analysis of taxol-induced multidrug resistance in an ovarian cancer cell line

Methylation-associated Has-miR-9 Deregulation in Paclitaxel- Resistant Epithelial Ovarian Carcinoma

PGAM1 Modulates Paclitaxel-Resistance in Ovarian Cancer Cells Through Controlling Pyruvic Acid Production in Glycolysis

The Inhibition of UBC13 Expression and Blockage of the DNMT1-CHFR-Aurora A Pathway Contribute to Paclitaxel Resistance in Ovarian Cancer

CRTC2 promotes paclitaxel resistance by inducing autophagy in ovarian cancer in part via the PI3K-AKT signaling axis

Key genes and molecular mechanisms related to Paclitaxel Resistance

Quantitative proteomic analysis of mitochondria from human ovarian cancer cells and their paclitaxel-resistant sublines

Integrated Analysis of Gene Expression Profiles Associated with Response of Platinum/paclitaxel-Based Treatment in Epithelial Ovarian Cancer.

MicroRNA Profile of Paclitaxel-Resistant Serous Ovarian Carcinoma Based on Formalin-Fixed Paraffin-Embedded Samples.

[The Selection of Taxol Resistance Associated Genes in Ovarian Cancer Cell Line by Mrna DD].

Exploring the resistance mechanism of triple-negative breast cancer to paclitaxel through the scRNA-seq analysis

&Lt;p>integrative Gene Expression Profiling Reveals That Dysregulated Triple Micrornas Confer Paclitaxel Resistance in Non-Small Cell Lung Cancer Via Co-Targeting MAPT</p>

Erratum: A2780 human ovarian cancer cells with acquired paclitaxel resistance display cancer stem cell properties.